Improving transplant opportunities for patients who are sensitised

Recruitment & Eligibility

Status: Suspended

Sex: All

Target Recruitment: 38

Inclusion Criteria

1. Aged 18 – 65 years
2. Able to give informed consent and willing to fulfil trial requirements
3. Completed the necessary assessments to receive a renal transplant
4. In stable health, as determined by the Investigator based on medical history and laboratory tests during the screening period
5. Negative serological test for hepatitis B (surface antigen and core antibody) and hepatitis C within the last 6 months, and HIV within the last 12 months
6. Documented immune status to varicella zoster virus (VZV) (at any time)
7. Female participant of childbearing potential must be willing to use a highly effective method of contraception for one year following rituximab (this period will also include the recommended 3 month period for avoidance of pregnancy following bortezomib). Male participants must be willing to use a highly effective form of contraception for 3 months post last dose of bortezomib
8. Persistent (for at least one year) and stable (tested on at least three occasions over the preceding year) circulating HLA antibodies defined by Luminex Single Antigen Bead analysis at the time of recruitment
9. Recipients awaiting deceased donor transplantation must have cRF >85% and at least 3 years on the transplant waiting list
10. Recipients with an HLA incompatible living donor who have been considered for enrolment in the UK Living Kidney Sharing Scheme must fit either of the following:
10.1. cRF is >95%
10.2. cRF is =85% and they have received no offers after three runs in the NLDKSS

Exclusion Criteria

1. Pregnancy, planned pregnancy during the trial period, or current breast feeding
2. Active viral, bacterial or fungal infection precluding immunosuppression
3. Active malignant disease
4. Listed for transplantation of any organ other than kidney alone
5. History of active or clinically significant respiratory, gastrointestinal (including pancreatitis), hepatic, cardiac,
neurological, psychiatric, musculoskeletal, genitourinary, dermatological, or other disorder that, in the Investigator’s
opinion, could affect the conduct of the trial
6. History of non-adherence, alcohol or substance abuse that, in the judgment of the Investigator, may impair or risk the subject’s full participation in the trial
7. Positive serological test for hepatitis B, C or HIV
8. Negative serological test for VZV
9. Previous graft loss to recurrent primary disease within 2 years of transplantation
10. Documented intolerance of bortezomib, rituximab or their exipients, or dexamethasone
11. Persistent thrombocytopaenia, platelet count <100 X 109/L for the past 3 consecutive months
12. Persistent neutropaenia, absolute neutrophil count < 2 X 109/L for the past 3 consecutive months
13. Hypogammaglobulinaemia, serum IgG less than local laboratory lower limit of normal at screening
14. Peripheral neuropathy of any grade (reported by symptoms or on clinical examination)
15. Currently involved in any other clinical trial of an IMP or have taken an IMP within 30 days prior to trial entry

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials